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Abstract
The paracrine networks of the human melanoma microenvironment are able to influence tumor growth and progres-
sion. Among the paracrine growth factors involved in skin homeostasis, the KGF/FGF7 secreted by dermal fibroblasts
promotes the epidermal proliferation and differentiation as well as the release from keratinocytes of other paracrine
mediators. To evaluate the possible role played by KGF in affecting the behavior of different subtypes of melanoma
carrying activating mutations or overexpression of the SCF receptor c-KIT, we used human melanoma cell lines, char-
acterized by different expression levels of c-KIT and opposing responsivity to SCF, and HaCaT keratinocytes. Quanti-
tative real-time reverse transcription–polymerase chain reaction assay and ELISA test on KGF-treated keratinocytes
showed enhanced expression and secretion of SCF in response to KGF and dependent on functional KGF receptor.
Immunofluorescence microscopy and biochemical analysis showed, in one of the selected melanoma cell models,
SCF-dependent c-KIT activation induced by stimulation with the culture supernatants collected from KGF-treated
keratinocytes. In keratinocyte-melanoma cocultures stained for the Ki67 proliferation marker, incubation with KGF in-
duced enhanced growth not only of the keratinocytes but also of the melanoma cells, which could be blocked by the
c-KIT inhibitor imatinib, demonstrating the establishment of a KGF-induced paracrine signaling network owing to the
coexpression of biologically active SCF released from keratinocytes and functional c-KIT on melanoma cells.
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Introduction
Melanoma is a complex neoplasia characterized by high genetic and cell
signaling heterogeneity [1,2]. Different activating mutations of critical
genes that regulate the signal transduction, such as BRAF andNRAS, or
amplification/overexpression of other oncogenes, such as CDK4, occur
frequently in distinct subsets of melanomas [1,3–5]. Among these
oncogenic alterations, activating mutations and overexpression of
c-KIT represent key events in defined subgroups of melanomas, that
is, acral and mucosal melanomas of the skin, cutaneous melanomas aris-
ing on chronic sun-damaged sites and uveal melanomas [6–11].
The c-KIT protein is a receptor tyrosine kinase that signals in response
to its ligand SCF. In normal human melanocytes, binding of paracrine
SCF to c-KIT induces receptor dimerization and phosphorylation
[12]. Activation of c-KIT leads to the recruitment of signaling pro-
teins and triggering of different pathways, such as the phosphoinositide
3-kinase/protein kinase B (AKT) and the mitogen-activated protein
kinase cascade, involved in the control of cell proliferation and survival
[12]. It is well known that these activated signaling pathways are critical
in melanoma progression [13,14] and the potential targeted therapeutic
strategies directed to inhibit them are of great clinical interest [14]. In
fact, the small-molecule c-KIT inhibitor imatinib has been used in sev-
eral clinical trials for c-KIT–positive melanoma therapy, although the
results of these studies have raised conflicting results [11,15–18].
Recently, it has been recognized that the tumor microenvironment,
with its paracrine network of growth factors and cytokines, may dra-
matically influence the tumor growth and progression [19]. Therefore,
a better knowledge of the melanoma-associated skin microenvironment,
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generated by the dermal-epidermal interactions and by the cell-cell com-
munications, and of the role of fibroblasts and keratinocytes in affecting
the tumor behavior is needed. Among the paracrine growth factors that
play crucial roles in regulating skin homeostasis and wound healing, the
KGF/FGF7 is known to promote epidermal proliferation and differen-
tiation [20,21] as well as cell survival andmotility [22–25]. Secreted from
mesenchymal cells, KGFacts specifically on epithelial cells through exclu-
sive binding to the KGFR, a spicing transcript variant of the fibroblast
growth factor receptor 2 (FGFR2) [26,27]. We have recently reported
that KGF is also able to promote the melanosome transfer from melano-
cytes to keratinocytes by a receptor-mediated stimulation of the phago-
cytic uptake process in the recipient cells [28,29]. Because of the broad
variety of effects exerted by the fibroblast-produced KGF in the skin
microenvironment, the aim of the present study was to evaluate the pos-
sible contribution of this growth factor in modulating indirectly the
growth of melanoma cells, through the activation of a paracrine net-
work. Because c-KIT represents a highly promising therapeutic target
and various cultured melanoma cell models that display heterogeneity
in c-KIT activating mutations or overexpression are available, we fo-
cused our attention on the triggering of the SCF/c-KIT axis in response
to paracrine KGF.
Materials and Methods
Cells and Treatments
The human keratinocyte cell line HaCaTand the human melanoma
cell line Mel 501 [30] were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum (FBS) and anti-
biotics. The human melanoma cell lines MST-L and MST-F (kindly
provided by Dr. Armando Bartolazzi, Ospedale Sant’Andrea, Rome,
Italy) were cultured in RPMI supplemented with 10% FBS and anti-
biotics. In cocultures, HaCaTand melanoma cells were seeded at a ratio
of 20:1 and were maintained in Dulbecco’s modified Eagle medium
with 10% FBS and antibiotics.
To evaluate SCF messenger RNA (mRNA) expression, HaCaT cells
were serum-starved for 12 hours and then incubated for 6 hours at
37°C with 20 ng/ml recombinant human KGF (Upstate Biotechnol-
ogy, Lake Placid, NY). Alternatively, cells were treated for 12, 24, and
48 hours at 37°C with 20 ng/ml KGF or kept untreated in serum-free
medium for the same time points. For the inhibition of KGFR, cells
were preincubated with a specific FGFR tyrosine kinase inhibitor
SU5402 (25 μM; Calbiochem, Nottingham, UK) for 1 hour before
incubating with the KGF diluted in the presence of SU5402. To esti-
mate SCF secretion in the supernatant (SN), HaCaT cells were treated
for 24 and 48 hours with 20 ng/ml KGF at 37°C in the presence or
absence of SU5402 as above or kept untreated in serum-free medium
for the same time points. The SNs were then collected and frozen at
−30°C until use.
To induce c-KIT activation, melanoma cells were serum-starved for
12 hours and then treated for 10 minutes at 37°C with 100 ng/ml re-
combinant human SCF (PeproTech, London, UK). For the inhibition
of c-KIT activity, cells were preincubated with the tyrosine kinase in-
hibitor imatinib (10 μM; Novartis, West Sussex, UK) for 24 hours
[31] before incubating with SCF diluted in the presence of imatinib
or with imatinib alone. Alternatively, melanoma cells were stimulated
for 10 minutes at 37°C with the SNs collected from HaCaT cells
untreated, treated with KGF for 48 hours, or treated with KGF for
48 hours in the presence of SU5402 as above. To block c-KIT activity,
melanoma cells were pretreated with imatinib for 24 hours and then in-
cubated with the SNs for 10minutes at 37°C in the presence of imatinib.
For proliferation assays, cocultures of HaCaT and melanoma cells
were treated for 48 hours at 37°C with 20 ng/ml KGF or preincubated
for 24 hours with imatinib and then incubated with 20 ng/ml KGF for
48 hours in the presence of imatinib. Alternatively, cells were treated
with 50 ng/ml SCF for 48 hours or preincubated with SU5402 for
1 hour at 37°C before incubating with SCF for 48 hours in the presence
of SU5402.
Human SCF ELISA
HaCaT cells grown to confluence were incubated with 20 ng/ml KGF
for 24 and 48 hours in the presence or absence of SU5402 as above.
SCF in SNs from HaCaT cells was quantified using the SCF ELISA
kit (Quantikine High Sensitivity Human; R&D Systems, Minneapolis,
MN) according to the manufacturer’s protocol. The human SCF Quan-
tikine Kit was a Sandwich ELISA–based quantification assay, and the
absorbance was measured at a wavelength of 450 nm, with the correc-
tion at 540 nm, within 30 minutes using a microplate reader (μQuant;
BioTek Instruments, Inc, Winooski, VT). A standard curve for each
ELISA experiment was prepared from triplicate wells with increasing
concentrations of SCF (0-7, 8-15, 6-31, 2-62, 5-125-250-500 pg/ml),
using the protocol described above. As negative controls, the pri-
mary antibodies were omitted and replaced with phosphate-buffered
saline (PBS). The results were normalized for the number of cells
contained in each sample and were expressed as picograms per 1 ×
106 cells. Each sample was analyzed in triplicate. Student’s t test was per-
formed to evaluate significant differences. P < .05 was considered statis-
tically significant.
Real-time Polymerase Chain Reaction Primer Design
Oligonucleotide primers for SCF target gene and GAPDH house-
keeping gene were chosen with the assistance of the Oligo 5.0 computer
program (National Biosciences, Plymouth, MN). For SCF gene, the
primers 5′-AAGAGGATAATGAGATAAGTATGTTGC-3′ (sense;
position863-245) and5′-TTACCAGCCAATGTACGAAAGT-3′ (anti-
sense; position 966-987) were used, yielding a complementary DNA
(cDNA) product of 104 bp in length, as given by GenBank accession
number NM_003994. GAPDH amplification was performed with
5′-TCACCATCTTCCAGGAGCGA-3′ (sense; position 323-342)
and 5′-CAAATGAGCCCCAGCCTTCT-3′ (antisense; position 438-
457) primer pairs, giving an amplicon of 116 bp in length (NM_
002046.3). To exclude amplification of contaminating genomic DNA,
one of the two primers was placed at the junction between two exons.
Gel electrophoresis was used to verify the specificity of polymerase chain
reaction (PCR) amplicons. For each primer pair, we performed no-
template control and no-reverse-transcriptase control (RT-negative)
assays, which produced negligible signals (usually >45 in threshold cycle
[C t] value), suggesting that primer-dimer formation and genomic DNA
contamination effects were negligible.
RNA Extraction
RNAwas extracted using theTRIzolmethod (Invitrogen,Milan, Italy)
according to the manufacturer’s procedure. Briefly, cells were homoge-
nized in 1 ml of TRIzol reagent and extracted with 0.2 ml of CHCl3;
0.5 ml of isopropanol was added to the aqueous phase. RNA pellet was
washed in 75% ethanol and eluted with 0.1% diethylpyrocarbonate-
treated water. Total RNA quantity, purity, and absence of ribonu-
clease digestion were assessed by measuring the optical density ratio at
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260/280 nm and by agarose gel electrophoresis. Total RNA samples were
stored at −80°C.
cDNA Synthesis
After denaturation in diethylpyrocarbonate-treated water at 70°C for
10 minutes, 1 μg of total RNA was reverse-transcribed using a reac-
tion mix of ImProm-II 5× reaction buffer containing 1.5 mM MgCl2,
0.5 mM dNTP, 20 U of RNase inhibitor (Promega, Madison, WI),
1 μl of ImProm-II Reverse Transcriptase (Promega), and 0.5 μg of
oligo(dT) primers. First-strand cDNA synthesis was carried out in a final
volume of 20 μl, incubating at 25°C for 5 minutes and at 42°C for
60 minutes, and inactivating reverse transcriptase by heating at 70°C
for 15 minutes and cooling at 5°C for 5 minutes.
PCR Amplification
Real-time PCR was performed using the iCycler Real-time Detec-
tion System (iQ5; Bio-Rad, Hercules, CA) with optimized PCR con-
ditions. The reaction was carried out in a 96-well plate using iQ SYBER
Green Supermix 2× (Bio-Rad) adding each forward and reverse primers
and 1 μl of diluted template cDNA to a final reaction volume of 15 μl.
Oligonucleotide primers were purchased from Invitrogen. All assays
included a negative control, and all were replicated three times. The
relative expression of GAPDH was used for standardizing the reaction.
The thermal cycling conditions comprised an initial denaturation step
at 95°C for 3 minutes, followed by 45 cycles at 95°C for 10 seconds and
at 60°C for 30 seconds.
Data Analyses
Real-time quantitation was performed by using SYBR Green dye as
fluorescent signal, with the help of the iCycler IQ optical system software
version 3.0a (Bio-Rad) according to the manufacturer’s manual. Quan-
titative values are obtained from the C t number at which the increase in
signal associated with exponential growth of PCR products starts to be
detected. Target gene (SCF ) amplification was compared with simulta-
neous amplification of an endogenous reference gene (GAPDH ), and
each sample was normalized on the basis of itsGAPDH content. For data
analyses, the C t values were exported into a Microsoft Excel Worksheet
(Microsoft Corporation, Redmond, WA). Results, expressed as the
amount of target gene expression relative to the housekeeping gene, were
calculatedwith theΔΔC t method and indicated as 2
−ΔΔC t. TheΔC t value
of the sample was determined by subtracting the average C t value of
the SCF target gene from the average C t value of the GAPDH gene
and normalized on the ΔC t value of the untreated control sample. For
the untreated control sample, the amount of target gene expression equals
1.0, by definition. Results are reported as mean ± SD from three differ-
ent experiments in triplicate. Statistical analysis was performed using
Student’s t test. P < .05 was considered statistically significant.
Western Blot Analysis
Subconfluent cultures of HaCaT,Mel 501,MST-L, andMST-F cells
were lysed in a buffer containing 50 mM HEPES pH 7.5, 150 mM
NaCl, 1% glycerol, 1% Triton X-100, 1.5 mMMgCl2, 5 mM EGTA,
supplemented with protease inhibitors (10 μg/ml aprotinin, 1 mM
phenylmethyl sulfonyl fluoride, 10 μg/ml leupeptin), and phosphatase
inhibitors (1 mM sodium orthovanadate, 20 mM sodium pyrophos-
phate, 0.5 M NaF); 50 μg of total protein was resolved under reducing
conditions by 7% SDS-PAGE and transferred to a reinforced nitro-
cellulose (BA-S 83; Schleider & Schuell, Keene, NH). The membranes
were blocked with 5% nonfat dry milk in PBS 0.1% Tween 20 and
incubated with anti–c-KIT, CD117 (Dako, Carpinteria, CA) or with
anti–phospho-c-KIT Tyr719 (Cell Signaling, Cambridge, MA), poly-
clonal antibodies followed by enhanced chemiluminescence detection
(ECL; Amersham, ArlingtonHeights, IL). To estimate the protein equal
loading, the membranes were rehydrated by being washed in PBS–
Tween 20, stripped with 100 mM mercaptoethanol and 2% SDS for
30minutes at 55°C, and probed again with antiactin (Sigma Chemicals,
St Louis, MO) monoclonal antibody.
Immunofluorescence
Melanoma cells grown on coverslips and incubated for 10 minutes at
37°C with 100 ng/ml SCF in the presence or absence of imatinib as
above or with SNs from HaCaTmonolayers (collected from untreated,
treated with KGF or with KGF + SU5402 cells) in the presence or
absence of imatinib as above were fixed in methanol for 4 minutes. Co-
cultures of HaCaT and melanoma cells grown on coverslips incubated
for 48 hours at 37°C with 20 ng/ml KGF in the presence or absence of
imatinib or incubated with 50 ng/ml SCF in the presence or absence
of SU5402 were fixed with 4% paraformaldehyde followed by treat-
ment with 0.1 M glycine for 20 minutes at 25°C and with 0.1% Triton
X-100 for an additional 5 minutes at 25°C to allow permeabilization.
Cells were then incubated for 1 hour at 25°C with the following pri-
mary antibodies: anti–c-KIT (1:50 in PBS; Dako) antityrosinase (1:50
in PBS; Santa Cruz Biotechnology, Inc, Santa Cruz, CA) and anti-
Ki67 (1:50 in PBS; Zymed Laboratories, Inc, San Francisco, CA) poly-
clonal antibodies and antiphosphotyrosine (1:100 in PBS; Upstate) and
anticytokeratins (1:100 in PBS; clone MNF116; Dako) monoclonal
antibodies. Nuclei were stained with 4′,6-diamidino-2-phenylindole
(1:10,000 in PBS; Sigma). The primary antibodies were visualized,
after appropriate washing with PBS, using goat antimouse immuno-
globulin G (IgG)–fluorescein isothiocyanate (FITC, 1:50 in PBS; Cappel
Research Products, Durham, NC), goat antirabbit IgG-FITC (1:500 in
PBS; Cappel), donkey antirabbit IgG–Alexa Fluor 594 (1:1000 in PBS;
Molecular Probes, Eugene, OR), and chicken antigoat IgG–Alexa Fluor
488 (1:1000 in PBS;Molecular Probes). Coverslips were finally mounted
with Mowiol (Calbiochem, Merck, Darmstadt, Germany) for observa-
tion. Fluorescence signals were analyzed by recording andmerging stained
images using a CCD device SPOT-2 camera (Diagnostic Instruments,
Inc, Sterling Heights, MI) and IAS2000/H1 software (Delta Sistemi,
Rome, Italy). Quantitative analysis of the phosphotyrosine fluorescence
intensity was performed by the analysis of 50 cells for each sample in five
different fields randomly taken from three different experiments. Percent-
age of Ki67-positive cells in cocultures of keratinocytes and melanoma
cells was analyzed counting for each treatment a total of 500 cells, ran-
domly observed in 10 microscopic fields from three different experi-
ments. Results have been expressed as mean values ± SE. Significance
was calculated using Student’s t test: P values < .05 were considered
statistically significant. Alternatively, cells were scanned in a series of
0.5-μm sequential sections with an ApoTome System (Zeiss, Ober
Kochen, Germany) connected with an Axiovert 200 inverted microscope
(Zeiss); image analysis was then performed by the Axiovision software
(Zeiss), and a three-dimensional reconstruction was obtained.
Results
KGF Treatment of Human Keratinocytes Induces SCF
Expression and Release
The keratinocytes of human skin produce both membrane type and
soluble SCF [32,33]. In particular, HaCaT keratinocytes represent an
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in vitro source of SCF and its release is increased by cell differentiation
[33]. To evaluate if treatment of HaCaT cells with KGF would induce
SCF production, we assessed the presence of SCF transcripts in HaCaT
cells by quantitative real-time reverse transcription–PCR (RT-PCR)
and GAPDH was used as housekeeping gene: SCF mRNA extracted
from cells stimulated with KGF for different time points (6, 12, 24,
and 48 hours) was quantitated and compared with that from untreated
control HaCaT cells. In KGF-stimulated cells, a significant increase
in mRNA SCF expression compared with control cells was observed
at 12 hours of treatment (P < .05). After 24 hours, the transcript levels
appeared decreased but still significantly higher in comparison to un-
treated cells (P < .05). No differences were observed after 48 hours
(Figure 1A). To demonstrate the direct effect of KGF in inducing SCF
expression, the quantitative RT-PCR assay was also performed in cells
treated with the growth factor in the presence or absence of the spe-
cific FGFR tyrosine kinase inhibitor SU5402: the results showed that
the presence of the inhibitor was able to inhibit the SCF up-regulation
(P < .05; Figure 1A).
The enhanced expression of SCF induced by KGF was also vali-
dated at the protein level by ELISA assay evaluating the amount of
Figure 1. Expression of SCF in HaCaT cells treated with 20 ng/ml KGF for different time points (6, 12, 24, and 48 hours) in the presence or
absence of the KGFR inhibitor SU5402 (25 μM). (A) Relative expression level of SCF evaluated by real-time quantitative RT-PCR. SCF/GAPDH
mRNA ratio was calculated with the ΔΔC t method as described inMaterials andMethods. The values of samples treated with KGF for 6, 12,
24, and 48 hours were expressed relative to untreated control samples as normalized fold expression. A significant increase in mRNA SCF
expressionwas observed at 12 and 24 hours. Results represent themean values± SD from three different experiments. Student’s t test was
performed to evaluate significant differences. (B) SCF quantitation by ELISA assay on supernatants from HaCaT cells treated as described.
The amount of SCF released in themedium resulted to be significantly increased after the treatment with KGF for 48 hours. The presence of
the inhibitor SU5402 was able to revert such stimulation. Student’s t test was performed to evaluate significant differences.
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secreted SCF in the culture SNs at 24 and 48 hours of treatment
with KGF. We observed a significant increase in SCF released at
48 hours (181.38 pg/1 × 106 cells) with respect to untreated control cells
(137.09 pg/1 × 106 cells; P < .05). Pretreatment with SU5402 showed
to repress the augmented secretion of SCF (19.31 pg/1 × 106 cells;P < .01
vs KGF; Figure 1B), indicating that KGFR and its signaling are specifi-
cally involved in the modulation of SCF. Although at 24 hours, the SCF
mRNA expression level in KGF-stimulated cells is higher than that in
control cells, the SCF secretion is lower in KGF-treated cells with respect
to the untreated cells (Figure 1B): because HaCaT cells are known to
produce both membrane type and soluble SCF [33], the transcript ex-
pression increased by KGF at 24 hours could correlate better with the
Figure 2. Different expression of c-KIT in human melanoma cell lines. (A) Mel 501, MST-F, and MST-L melanoma cells were lysed and
processed for Western blot analysis using anti–c-KIT polyclonal antibodies to detect the endogenous protein: a band of 145 kDa
corresponding to the molecular weight of c-KIT protein is visible in MST-F and MST-L melanoma cells but not in Mel 501 cells, and
in HaCaT human keratinocytes used as negative control. Equal loading was assessed by stripping the blots and reprobing with antiactin
monoclonal antibody. (B) Mel 501, MST-F, and MST-L cells and HaCaT keratinocytes were fixed, permeabilized as described in Materials
and Methods, and immunolabeled with anti–c-KIT polyclonal antibodies followed by FITC-conjugated secondary antibodies. Cell nuclei
were visualized by DAPI. Immunofluorescence microscopical analysis shows that in both MST-F and MST-L cells, the staining for c-KIT
protein is intense and localized on the cell plasma membrane as well as in the juxtanuclear Golgi area or in small dots scattered through-
out the cell periphery. In contrast, no c-KIT immunostaining is detectable in Mel 501 and HaCaT cells. Bar, 10 μm.
Figure 3. Tyrosine phosphorylation in melanoma cells induced by incubation with SCF or with supernatants collected from KGF-treated
HaCaT cells. (A) MST-L, MST-F, and Mel 501 cells were serum-starved for 12 hours, treated with 100 ng/ml SCF for 10 minutes or preincu-
bated for 24 hours with the c-KIT inhibitor imatinib (10 μM), and then treated with SCF as above in presence of imatinib. Cells were stained
with anti-PY monoclonal antibody followed by FITC-conjugated secondary antibodies and with DAPI to visualize the cell nuclei. Quantitative
immunofluorescence analysis of the fluorescence intensity, performed as described in Materials and Methods, shows in MST-L cells an
increase of the phosphotyrosine staining at the cell plasmamembrane induced by SCF stimulation, which is drastically reduced by pretreat-
ment with imatinib, demonstrating that the signal ismostly due to c-KIT activation induced by the SCF ligand. Either the low phosphotyrosine
fluorescence staining observed in MST-F cells or the basal intense staining evident in Mel 501 cells does not seem modified by SCF stimu-
lation or imatinib treatment. Bar, 10 μm. (B) MST-L, MST-F, and Mel 501 cells were serum-starved for 12 hours and treated for 10 minutes
with different SNs collected from confluent cultures of HaCaT cells. Alternatively, cells were serum-starved for 12 hours, preincubated for
24 hours with imatinib, and then treated with the SNs collected from KGF-treated cells. Cells were then stained with antiphosphotyrosine
monoclonal antibody. Immunofluorescence microscopical analysis and quantitative analysis of the fluorescence intensity in MST-L cells
reveals an increase in the phosphotyrosine signal upon stimulation with SNs from untreated HaCaT cells and, much more, with SNs from
KGF-treated HaCaT cells compared with the basal signal of serum-starved MST-L cells. The staining obtained by incubating with SNs from
KGF-treated HaCaT cultures is strongly decreased by imatinib pretreatment, demonstrating that the phosphotyrosine signal is dependent
on SCF present in the SN and corresponds to c-KIT activation. No significant increase in the signal is evident upon stimulation with SNs from
HaCaT cells treated with KGF in the presence of the KGFR inhibitor SU5402, testifying the specificity of the KGF’s effect on SCF secretion
from HaCaT keratinocytes. In contrast, either the basal weak phosphotyrosine fluorescence signal observed in MST-F cells or the basal
intense staining evident in Mel 501 cells does not seem to be significantly affected by stimulation with the different SNs. Bar, 10 μm. Stu-
dent’s t test was performed, and significance level has been defined as *P< .05 versus the corresponding untreated cells; **P< .05 versus
the corresponding SCF treated cells; ^P< .05 versus the corresponding cells incubated with the SNs from untreated HaCaT cells; ^^ P<
.05 versus the corresponding cells incubated with the SNs from KGF-treated HaCaT cells. (C) MST-L melanoma cells were lysed and pro-
cessed for Western blot analysis using anti–phospho-c-KIT and anti–c-KIT antibodies to detect the active form and the total protein: c-KIT
phosphorylation is visible after incubating with SCF or with the SN from KGF-treated HaCaT cells but not in control unstimulated cells or in
cells treated with SCF in the presence of imatinib. Equal loading was assessed with antiactin monoclonal antibody.
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membrane form than with the secreted form of SCF. In addition, the
increased SCF release observed in HaCaT cells at 48 hours compared
with that observed at 24 hours is consistent with previous report that
describes a higher secretion of SCF in differentiating versus proliferating
cells [33].
Thus, KGF is able to induce up-regulation of SCF gene expression in
HaCaT cells and increased release of soluble SCF, which, in turn, might
exert a paracrine action on melanocytes.
SCF Induces c-KIT Activation in Melanoma Cells
To analyze the possible role of soluble SCF secreted by KGF-treated
keratinocytes on melanoma cells, we selected three different melanoma
cell lines, Mel 501, MST-L, and MST-F cells, expressing high or low
levels of c-KIT. The expression of c-KIT protein was first evaluated by
Western blot analysis using anti–c-KIT polyclonal antibodies: a specific
band of 145 kDa corresponding to the molecular weight of c-KIT pro-
tein was visible in MST-F and MST-L melanoma cells, but not in Mel
501 cells and in HaCaT human keratinocytes used as negative control
(Figure 2A). To assess equal loading, blots were stripped and reprobed
with antiactinmonoclonal antibody (Figure 2A). To confirm the different
expression of c-KIT in the selected cell models and to verify the correct
localization of the receptor on the plasma membranes of the positive
cells, we performed an immunofluorescence microscopical analysis with
the anti–c-KIT antibodies: in MST-F and MST-L cells, the immuno-
staining appeared intense and localized on the cell plasma membrane
and in the juxtanuclear Golgi area. Immunolabeling was also visible in
small dots scattered throughout the cell periphery, possibly correspond-
ing to intracellular transport structures of the exocytic or endocytic
compartments (Figure 2B). In contrast, no c-KIT immunostaining was
detectable in Mel 501 and HaCaT cells (Figure 2B), confirming the
biochemical results described above.
Binding of SCF to the c-KIT tyrosine kinase is known to induce ty-
rosine autophosphorylation and activation of the receptor. To determine
whether the c-KIT proteins expressed onMST-L andMST-Fmelanoma
cells would be constitutively activated, as it occurs in a subset of melano-
mas expressing oncogenic mutations of the KIT gene [6], or would un-
dergo tyrosine phosphorylation only in response to SCF, we performed
a quantitative immunofluorescence microscopical analysis of MST-L,
MST-F, and Mel 501 cells with antiphosphotyrosine monoclonal anti-
body: cells were serum-starved and treated with SCF for 10 minutes at
37°C before immunolabeling or with SCF in the presence of the small-
molecule c-KIT inhibitor imatinib [9]. In both untreated MST-L and
MST-F cells, a very weak intensity of the signal was observed, suggesting
a low amount of constitutive activation of receptor tyrosine kinases,
whereas the PY signal of Mel 501 was intense also in untreated serum-
starved conditions, revealing constitutive phosphotyrosine activation of
receptors other than c-KIT (Figure 3A). SCF stimulation of MST-L
cells induced a high increase of the PY staining at the cell plasma mem-
branes, which was drastically reduced by pretreatment with imatinib
(Figure 3A), suggesting that the immunofluorescence signal decorating
the cell surface is mostly due to functional c-KIT activation induced by
the SCF ligand. In contrast, treatment with SCF of MST-F cells did not
seem to trigger c-KITactivation (Figure 3A) and theMel 501 cell line was
not significantly affected by SCF stimulation or imatinib treatment.
Thus, the three selected melanoma cell lines seem to represent three dif-
ferent models of melanoma behavior: 1) MST-L as melanoma cells with
Figure 3. (continued).
Figure 4. Proliferation of melanoma cells cocultured with HaCaT keratinocytes. Cocultures of MST-L, MST-F, or Mel 501 cells with HaCaT
keratinocytes were plated at a seeding ratio of 1:20. (A) Double immunofluorescence staining was performed with anti–tyrosinase poly-
clonal antibodies (green) to unequivocally identify melanoma cells and with anticytokeratin monoclonal antibody (red) to recognize HaCaT
keratinocytes. Cell nuclei were visualized by DAPI. The immunofluorescence analysis was performed by serial optical sectioning and three-
dimensional reconstruction as described in Materials and Methods. Images obtained by three-dimensional reconstruction of a selection of
three of the total number of the serial optical sections are shown: the selected sequential sections are central and crossing the nucleus. The
tyrosinase-positive dots corresponding to melanosomes are localized in the cytoplasm of melanoma cells, which are surrounded by HaCaT
keratinocytes containing bundles of cytoplasmic keratin filaments. Bar, 10 μm. (B) Cocultured cells were serum-starved for 12 hours, treated
with 20 ng/ml KGF for 48 hours or with 50 ng/ml SCF for 48 hours also in the presence of imatinib or SU5402 to inhibit c-KIT expressed on
melanoma cells or KGFR expressed on HaCaT keratinocytes, respectively. Cocultures were stained with anti-Ki67monoclonal antibody (red)
to detect the proliferating cells and with anti-tyrosinase polyclonal antibody (green) to identify the melanoma cells. Quantitative analysis of
the percentage of cycling cells displaying the nuclear Ki67 positivity was performed as described in Materials and Methods. In cocultures of
MST-L and HaCaT cells, addition of KGF causes a drastic increase in the percentage of cycling Ki67-positive nuclei in both types of cells,
demonstrating that KGF is able to induce a paracrine network. Cotreatment of KGF with imatinib specifically blocks melanoma prolifera-
tion confirming the involvement of SCF release by keratinocytes in the activation ofMST-L cells. Addition of SCF induces not onlymelanoma
cell growth, as expected, but also proliferation of HaCaT keratinocytes that is selectively inhibited by cotreatment with SU5402, suggesting
the possible release of KGFR ligands from melanoma cells. In cocultures of MST-F and HaCaT cells, addition of KGF causes exclusively
proliferation of HaCaT cells, and incubation with SCF does not stimulate melanoma cells, revealing no induction of a paracrine network
and confirming the inability of c-KIT expressed in these cells to respond to SCF. In contrast, the coculture of Mel 501 with HaCaT cells
leads to the induction of a paracrine network also in untreated conditions, demonstrating that such cell-cell interaction is independent of
KGF and SCF/c-KIT. Bar, 10 μm. Student’s t test was performed and significance level has been defined as *P< .05 versus the correspond-
ing untreated cells; **P< .05 versus the corresponding KGF-treated cells; ^P< .05 versus the untreated cells; ^^ P< .05 versus the SCF-
treated cells.
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SCF-inducible c-KIT activation, 2) MST-F as cells with c-KIT not re-
sponding to the ligand SCF, and 3) Mel 501 as cells with constitutive
tyrosine phosphorylation and signaling activity independent of SCF
and c-KIT.
To ascertain if the soluble SCF released by HaCaT cells on KGF
stimulation would be biologically active in triggering c-KIT on me-
lanoma cells, we used the three cell lines characterized above for
their distinct SCF/c-KIT axis and we incubated them with SNs
collected from KGF-treated HaCaT cultures. Melanoma cells were
then stained with antiphosphotyrosine monoclonal antibody as above.
Quantitative analysis of the fluorescence intensity revealed that in-
cubation of MST-L cells with the SNs from untreated HaCaT cultures
induced an increase of the phosphotyrosine signal compared to the
basal PY staining of serum-starved cells (Figure 3B) and the positive
signal was further raised by incubating with SNs from KGF-treated
HaCaT cells (Figure 3B). This intense staining obtained on stimu-
lation of MST-L cells with SNs from KGF-treated HaCaT cultures
was strongly reduced by imatinib, suggesting that the PY signal is
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dependent on the SCF released in the SNs and that it corresponds to
c-KIT activation (Figure 3B). Again, to demonstrate the direct role of
KGF in the up-modulation of SCF secreted in the SNs from cultures
of HaCaT keratinocytes, a specific block of KGFR signaling was
achieved through treatment of the HaCaT cells with KGF in the
presence of the KGFR inhibitor SU5402 before the collection of
the culture SNs: the immunofluorescence analysis showed no signif-
icant increase of the signal, confirming the specificity of the KGF
effect on SCF secretion (Figure 3B). The weak PY staining observed
in MST-F cells and the basal intense signal evident in Mel 501 cells
were not significantly affected by stimulation with the different SNs
(Figure 3B).
To confirm in MST-L cells the c-KITactivation induced by SCF re-
leased by the KGF-treated HaCaT cells and its specific inhibition by
imatinib, we performed a Western blot analysis using anti–phospho-
c-KITantibodies directed against the Tyr719 and recognizing the active
protein: c-KIT phosphorylation was evident in MST-L cells treated
with SCF or with the SNs from KGF-treated HaCaT cells and dras-
tically inhibited by imatinib (Figure 3C ). Equal loading was assessing
with antiactin monoclonal antibody (Figure 3C ).
Thus, c-KIT present on the MST-L melanoma cells is activated in a
paracrinemanner by keratinocyte-derived SCF, which, in turn, is secreted
in response to the paracrine action of KGF.
KGF and SCF Paracrine Loop in Cocultures
Cell-cell interactions and paracrine networks have been widely stud-
ied in vitro using coculture models of different cell types. Therefore, to
verify our hypothesis of the role of KGF in inducing the SCF/c-KITaxis
from the HaCaT keratinocytes to the selected melanoma cells charac-
terized above for their behavior on SCF stimulation and c-KIT activa-
tion, we coculturedMST-L, MST-F, or Mel 501 cells with HaCaT cells
at a seeding ratio of 1:20. To evaluate the cell growth, we performed
an immunofluorescence analysis for the quantitative detection of cells
positive for the Ki67 proliferation marker. To unequivocally identify
melanoma cells, we used antityrosinase polyclonal antibodies that deco-
rate the membranes of melanosomes, whereas to recognize the HaCaT
keratinocytes, we labeled the cultures with anticytokeratin monoclonal
antibody. Cells were then analyzed by serial optical sectioning and three-
dimensional reconstruction as described inMaterials andMethods. The
double immunofluorescence staining revealed tyrosinase-positive dots
corresponding to melanosomes in the cytoplasm of melanoma cells
and bundles of cytoplasmic keratin filaments in the HaCaT keratino-
cytes (Figure 4A).
Cocultured cells were treated with KGF (20 ng/ml for 48 hours) or
with SCF (50 ng/ml for 48 hours). Alternatively, cocultures were
incubated with KGF in the presence of imatinib to inhibit c-KIT
expressed on melanoma cells or with SCF in the presence of SU5402
to block the KGFR expressed on HaCaT keratinocytes. Cocultures
were then immunolabeled with anti-Ki67 monoclonal antibody to
detect all cycling cells and with antityrosinase antibody to visualize
the melanoma cells. Quantitative analysis of the percentage of cycling
cells displaying the nuclear Ki67 positivity was performed as described
in Materials and Methods. In cocultures of HaCaTwith MST-L cells,
the addition of KGF caused a drastic increase in the percentage of Ki67-
positive nuclei not only in the keratinocytes expressing the receptor but
also in the melanoma cells not expressing the KGFR, demonstrating
that KGF is able to induce a paracrine network (Figure 4B). Cotreat-
ment of KGF with imatinib specifically blocked melanoma prolifera-
tion, confirming the involvement of SCF released by keratinocytes in
the paracrine stimulation of MST-L cells. Interestingly, the addition of
SCF induced not only melanoma cell growth, as expected from the
expression of functional c-KIT in these cells, but also proliferation of
HaCaT keratinocytes, which was selectively inhibited by cotreatment
with SU5402, suggesting the possible release of KGFR ligands from
melanoma cells. In contrast, the addition of KGF to cocultures of
HaCaTwithMST-F cells was able to cause proliferation of HaCaT cells
only (Figure 4B), revealing no induction of a KGF-dependent paracrine
network. Moreover, the incubation with SCF did not stimulate either
HaCaTor MST-F cells, confirming the inability of c-KIT expressed in
these cells to respond to SCF. Finally, the coculture of HaCaT with
Mel 501 cells led to growth of both cell types also in untreated condi-
tions, demonstrating the existence of a constitutive paracrine network
independent of KGF and SCF/c-KIT.
Thus, KGF promotes the establishment of a paracrine SCF/c-KITaxis
from the HaCaT keratinocytes to melanoma cells expressing functional
c-KIT and a reverse cell-cell paracrine interaction leading to keratino-
cyte growth.
Discussion
Genetic alterations of c-KIT are known to be associated with several
neoplastic disorders including gastrointestinal stromal tumors, semi-
nomas, and mast cell leukemias [11]. Interestingly, the c-KIToncogene
seems to play opposing effects on different subtypes of melanoma: in
fact, in some tumors, c-KIT negatively regulates the growth and seems
to be down-modulated during progression [11], whereas in other sub-
groups of melanomas, c-KITactivating mutations or overexpression re-
sults in aberrant signaling that drives tumorigenesis [6–11]. In addition,
melanoma cells might either lose dependence on paracrine growth
factors, acquiring autocrine pathways of stimulation [19], or might
be able to respond to paracrine cross talk with an enhanced proliferation
[19,34]. Among the paracrine growth factors that may influence mela-
noma behavior, the c-KIT ligand SCF is one of the major mitogens for
melanocytes [32]. Here we have selected three distinct cell lines that
represent models of melanomas characterized by different expression
levels of c-KIT and different responsivity to the c-KIT ligand SCF:
the three cell models reflect the possible ways of involvement of the
SCF/c-KIT axis in the paracrine signaling network between normal
keratinocytes and melanoma cells, ranging from total independency
to dependency and inducibility by other networks. Because of this
heterogeneity in SCF/c-KITand the availability of therapeutic strategies
based on the treatmentwith the specific c-KIT inhibitor imatinib, which
are currently under clinical investigations, a deeper investigation on the
epidermal-derived or dermal-derived growth factors that may trigger the
SCF/c-KIT cross talk is needed.
Therefore, having characterized our cell models of melanoma and
their cocultures with keratinocytes, we wondered if one of the most
critical mediator of epidermal proliferation and differentiation, the
KGF/FGF7 derived from dermal fibroblasts, could be able to induce
an SCF/c-KIT–dependent signaling network. The results showed that
KGF, through the promotion of SCFexpression and secretion from con-
fluent differentiating keratinocytes, indirectly stimulates the growth of
melanoma cells in which c-KIT is expressed and is functionally active by
its ligand (Figure 5). This stimulation in two steps is justified by the
presence of KGF receptor exclusively on epithelial cells and its absence
on melanocytes. Moreover, the specificity of this network is demon-
strated by the selective inhibition of the KGF receptor on the keratino-
cytes or of c-KITon the melanoma cells (Figure 5).
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Multiple cytokines and growth factors are suspected to play roles in
the induction or progression of melanoma. Similar to KGF, the hepato-
cyte growth factor (HGF) is also secreted by dermal fibroblasts and acts
on epidermal cells; however, different fromKGF,HGF is able to directly
exert its scattering activity on melanocytes and melanoma cells promot-
ing tumorigenesis and invasion [34,35]. In addition, whereas several
growth factors, in general, and HGF, in particular, frequently become
responsible for autocrine loops of stimulation in tumor cells or in cells
of the tumor microenvironment [19], KGF has not been reported as
involved in known autocrine pathways. However, the possible contribu-
tion of KGF secreted in a paracrine manner by stromal cells surround-
ing a tumor with specific molecular gene signatures, such as the SCF/
c-KIT–dependent melanoma subgroups, remains to be established.
Finally, our results obtained by the coculture experiments clearly in-
dicate the existence of a reverse inducible paracrine interaction from
melanocytes to keratinocytes involving KGFR ligands. Although we
cannot exclude the release of other known ligands for KGFR, such as
FGF10, evidence for the expression of KGF in human malignant mela-
noma has been reported [36], suggesting the possible release of KGF
from the tumor that can stimulate keratinocyte proliferation. Because
it is well known that both KGF and FGF10 also induce keratinocyte
differentiation [21,37] and that SCF is released by more differentiated
keratinocytes [33], the suggested reverse signaling cross talk involving
KGFR ligands from melanoma to keratinocytes might further activate
and deregulate the SCF/c-KIT axis.
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